Longboard Pharmaceuticals, Inc.

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Although 2024 got off to a promising start with a busy first quarter, the fourth quarter marked the third consecutive quarter of declining biopharma merger-and-acquisition valuation. Evaluate reported

In the top alliance by deal value, Monte Rosa Therapeutics granted Novartis exclusive global rights to develop, manufacture and commercialize Phase I MRT-6160 for immune-mediated conditions as well as

Financial market conditions are beginning to improve for biopharmaceutical companies raising money to fund research and development programs, thanks in large part to an increase in mergers and acquisi